ES2174855T3 - Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos. - Google Patents

Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos.

Info

Publication number
ES2174855T3
ES2174855T3 ES93923752T ES93923752T ES2174855T3 ES 2174855 T3 ES2174855 T3 ES 2174855T3 ES 93923752 T ES93923752 T ES 93923752T ES 93923752 T ES93923752 T ES 93923752T ES 2174855 T3 ES2174855 T3 ES 2174855T3
Authority
ES
Spain
Prior art keywords
protein
nucleic acids
serrate
pharmaceutical compositions
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923752T
Other languages
English (en)
Other versions
ES2174855T5 (es
Inventor
Spyridon Artavanis-Tsakonas
Richard Grant Fehon
Panayiotis Zagouras
Christine Marie De Blaumueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26769466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2174855(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of ES2174855T3 publication Critical patent/ES2174855T3/es
Publication of ES2174855T5 publication Critical patent/ES2174855T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES Y METODOS TERAPEUTICOS Y DE DIAGNOSTICO BASADAS EN PROTEINAS DE INCISION Y ACIDOS NUCLEICOS. LA FIGURA 17 MUESTRA LAS SECUENCIAS DE UN DNA HUMANO DE INCISION Y LA PROTEINA HUMANA DE INCISION CODIFICADA. LA INVENCION PROPORCIONA PARA EL TRATAMIENTO DE ENFERMEDADES DE DESARROLLO O DIFERENCIACION CELULAR A TRAVES DE LA ADMINISTRACION DE UN COMPUESTO TERAPEUTICO DE LA INVENCION. TALES COMPUESTOS TERAPEUTICOS (DENOMINADOS AQUI "TERAPEUTICOS") INCLUYEN PROTEINAS DE INCISION Y ANALOGOS Y DERIVADOS (INCLUYENDO FRAGMENTOS) DE LOS MISMOS, ANTICUERPOS DE LOS MISMOS, ACIDOS NUCLEICOS CODIFICANDO LAS PROTEINAS DE INCISION, ANALOGOS, O DERIVADOS, ACIDOS NUCLEICOS ANTISENSIBLES DE INCISION, TAN BIEN COMO PROTEINAS TOPORITMICAS Y DERIVADOS QUE ENLAZAN O DE OTRA MANERA INTERACCIONAN CON PROTEINAS DE INCISION, SUS ACIDOS NUCLEICOS O ANTICUERPOS CODIFICADOS. EN UNA PUESTA EN PRACTICA PREFERENTE, SE ADMINISTRA UN TERAPEUTICO DE LA INVENCION PARA TRATAR UNA CONDICION CANCEROSA, O PARA PREVENIR LA PROGRESION DESDE UN ESTADO PRE-NEOPLASTICO O NO MALIGNO DENTRO DE UN ESTADO NEOPLASTICO O MALIGNO.
ES93923752T 1992-09-30 1993-09-30 Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos. Expired - Lifetime ES2174855T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83590 1987-08-10
US95501292A 1992-09-30 1992-09-30
US955012 1992-09-30
US08/083,590 US5786158A (en) 1992-04-30 1993-06-25 Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids

Publications (2)

Publication Number Publication Date
ES2174855T3 true ES2174855T3 (es) 2002-11-16
ES2174855T5 ES2174855T5 (es) 2009-05-01

Family

ID=26769466

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93923752T Expired - Lifetime ES2174855T5 (es) 1992-09-30 1993-09-30 Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos.
ES01120663T Expired - Lifetime ES2324641T3 (es) 1992-09-30 1993-09-30 Composiciones terapeuticas de anticuerpos y acidos nucleicos antisentido para serrate.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01120663T Expired - Lifetime ES2324641T3 (es) 1992-09-30 1993-09-30 Composiciones terapeuticas de anticuerpos y acidos nucleicos antisentido para serrate.

Country Status (11)

Country Link
US (2) US5786158A (es)
EP (4) EP0662827B2 (es)
JP (1) JP3851653B2 (es)
AT (2) ATE216225T1 (es)
AU (1) AU685067B2 (es)
CA (1) CA2145778C (es)
DE (2) DE69331832T3 (es)
DK (2) DK1175909T3 (es)
ES (2) ES2174855T5 (es)
PT (1) PT662827E (es)
WO (1) WO1994007474A1 (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
US5869282A (en) * 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20030225019A1 (en) * 2002-05-30 2003-12-04 Freier Susan M. Notch1 inhibitors for inducing apoptosis
WO1997001571A1 (en) * 1995-06-28 1997-01-16 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US20050158859A1 (en) * 1995-09-29 2005-07-21 Yale University Manipulation of non-terminally differentiated cells using the Notch pathway
US6887475B1 (en) 1996-11-07 2005-05-03 Lorantis Limited Notch
TR199901000T2 (xx) * 1996-11-07 1999-07-21 Lorantis Limited �entik.
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
ATE342358T1 (de) 1997-04-04 2006-11-15 Millennium Biotherapeutics Inc Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
US6436650B1 (en) 1997-07-23 2002-08-20 Yale University Activated forms of notch and methods based thereon
US6692919B1 (en) * 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
AU2342299A (en) * 1998-01-26 1999-08-09 Genquest Inc. Compositions and methods for detecting and treating breast cancer
JP2002526109A (ja) * 1998-10-02 2002-08-20 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ アポトーシス誘導物質と方法
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
AU6913100A (en) * 1999-08-19 2001-03-13 Chiron Corporation Notch receptor ligands and uses thereof
US6720173B1 (en) 1999-11-08 2004-04-13 Lexicon Genetics Incorporated Human kinase protein and polynucleotides encoding the same
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
GB9927331D0 (en) 1999-11-18 2000-01-12 Fluorescience Ltd Assay for measuring enzyme activity in vivo
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
WO2002006339A2 (en) * 2000-07-03 2002-01-24 Curagen Corporation Proteins and nucleic acids encoding same
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) * 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US20020151487A1 (en) * 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
US7399633B2 (en) * 2000-10-27 2008-07-15 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
US6649346B2 (en) 2001-03-30 2003-11-18 Board Of Regents, The University Of Texas Methods of identifying agents that affect cleavage of amyloid-β precursor protein
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
US20030138795A1 (en) * 2001-06-14 2003-07-24 Shujian Wu Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, BGS-8, expressed highly in immune tissue
WO2002102987A2 (en) * 2001-06-18 2002-12-27 The General Hospital Corporation Methods and compositions based on protein interactions with mastermind
US7214488B2 (en) * 2001-07-03 2007-05-08 United States Of America, Represented By The Secretary, Department Of Health And Human Services Detection of MECT1-MAML2 fusion products
GB0118155D0 (en) * 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
US20030148954A1 (en) * 2001-11-02 2003-08-07 Wisconsin Alumni Research Foundation Agents and methods for modulating activator protein-1-mediated cellular processes
US20050137130A1 (en) * 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
EP1446424A2 (en) * 2001-11-14 2004-08-18 Lorantis Limited Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system
EP1448599A2 (en) * 2001-11-14 2004-08-25 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
EP1461621A4 (en) * 2001-11-29 2005-11-23 Scripps Research Inst ENZYME ACTIVITY PROFILE
CA2469204A1 (en) * 2001-12-07 2003-06-19 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
US20040106566A1 (en) * 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
US20040101847A1 (en) * 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
US20040102390A1 (en) * 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch3 expression
US20050124572A1 (en) * 2002-06-17 2005-06-09 Freier Susan M. Compositions and their uses directed to signal tranducers
JP4558485B2 (ja) * 2002-07-18 2010-10-06 正康 大河内 Ｎｏｔｃｈ由来新規ポリペプチドおよびそれを用いたバイオマーカー並びに試薬
CA2497226A1 (en) * 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical compositions and medical treatments comprising notch ligand proteins
GB0300428D0 (en) * 2003-01-09 2003-02-05 Lorantis Ltd Medical treatment
GB0307472D0 (en) * 2003-04-01 2003-05-07 Lorantis Ltd Medical treatment
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005014854A1 (en) * 2003-08-08 2005-02-17 Licentia, Ltd. Materials and methods for colorectal cancer screening, diagnosis, and therapy
WO2005021783A2 (en) * 2003-08-30 2005-03-10 Adrian Merlo New use of gain and loss of notch2 function in brain tumors and the new notch2 genetic alterations of the notch2 gene per se
US7282203B2 (en) * 2003-11-26 2007-10-16 Health Research, Inc. Use of NOTCH pathway interfering agents for treatment of plasma cell disorders
AU2005209909B8 (en) * 2004-02-03 2009-01-15 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2006047878A1 (en) * 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007053577A2 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP5129149B2 (ja) * 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2008057144A2 (en) * 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
BRPI0717431A2 (pt) 2006-09-29 2013-11-12 Oncomed Pharm Inc Composições e métodos de diagnóstico e tratamento do câncer
US7700113B2 (en) * 2006-10-19 2010-04-20 Maine Medical Research Institute, A Division Of Maine Medical Center Inhibiting breast cancer cell growth by administering an intracellular domain of NOTCH2
CL2007002989A1 (es) 2006-10-19 2008-05-16 Genentech Inc Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3.
MX2009004106A (es) 2006-10-19 2009-04-28 Genentech Inc Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3.
EP2610267A1 (en) * 2006-12-18 2013-07-03 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
EP2155249A4 (en) 2007-05-15 2011-11-16 Oncomed Pharm Inc COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
JP5560270B2 (ja) 2008-07-08 2014-07-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ結合剤およびアンタゴニストならびにその使用方法
JP5792621B2 (ja) 2008-09-26 2015-10-14 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
TW201018484A (en) * 2008-10-01 2010-05-16 Genentech Inc Anti-Notch2 antibodies and methods of use
WO2010059543A1 (en) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
PE20121494A1 (es) 2009-06-18 2012-11-01 Pfizer Anticuerpos anti notch-1
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
WO2011063237A2 (en) 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP2523682B1 (en) 2010-01-13 2015-12-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
MX347515B (es) 2010-04-01 2017-04-28 Oncomed Pharmaceuticals Inc * Agentes que se unen al receptor encrespado y usos de los mismos.
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
MX346995B (es) 2010-12-15 2017-04-06 Wyeth Llc Anticuerpos anti-notch1.
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
AU2013343045A1 (en) 2012-11-07 2015-05-21 Pfizer Inc. Anti-Notch3 antibodies and antibody-drug conjugates
WO2014121196A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
US9689874B2 (en) 2015-04-10 2017-06-27 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
TWI713590B (zh) * 2015-09-26 2020-12-21 財團法人國家衛生研究院 Notch 訊息傳遞路徑之活化劑用於治療掉髮之用途及其組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5115096A (en) * 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein
US5132212A (en) * 1989-11-17 1992-07-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Scl gene, and a hematopoietic growth and differentiation factor encoded thereby
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
IL101728A (en) * 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5264557A (en) * 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
WO1993012141A1 (en) * 1991-12-11 1993-06-24 Yale University Nucleotide and protein sequences of the serrate gene and methods based thereon
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
ATE319827T1 (de) * 1995-11-17 2006-03-15 Asahi Chemical Ind Polypeptid, das die differenzierung unterdrueckt
EP0921818A4 (en) * 1996-05-31 2002-09-25 Nat American Red Cross THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON JAGGED / NOTCH PROTEINS AND AMINO ACIDS

Also Published As

Publication number Publication date
JP3851653B2 (ja) 2006-11-29
EP1175909A8 (en) 2002-08-21
DE69334266D1 (de) 2009-04-23
ES2174855T5 (es) 2009-05-01
ATE425181T1 (de) 2009-03-15
CA2145778A1 (en) 1994-04-14
ATE216225T1 (de) 2002-05-15
DK0662827T3 (da) 2002-08-12
EP1197220A3 (en) 2009-04-15
US6083904A (en) 2000-07-04
EP1175909B1 (en) 2009-03-11
ES2324641T3 (es) 2009-08-12
CA2145778C (en) 2012-04-17
EP1175909A3 (en) 2003-11-26
JPH08502170A (ja) 1996-03-12
EP0662827A4 (en) 1997-12-03
DK0662827T4 (da) 2009-04-20
EP0662827A1 (en) 1995-07-19
EP0662827B2 (en) 2009-01-07
PT662827E (pt) 2002-09-30
DK1175909T3 (da) 2009-07-06
EP1197220A2 (en) 2002-04-17
DE69331832T2 (de) 2002-12-19
EP2145897A3 (en) 2010-03-03
WO1994007474A1 (en) 1994-04-14
EP1175909A2 (en) 2002-01-30
EP2145897A2 (en) 2010-01-20
DE69331832D1 (de) 2002-05-23
DE69331832T3 (de) 2009-07-16
AU5350394A (en) 1994-04-26
US5786158A (en) 1998-07-28
EP0662827B1 (en) 2002-04-17
AU685067B2 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
ES2174855T3 (es) Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos.
EP1440980A3 (en) Peptide analogs of human myelin basic protein
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
DE69840195D1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
DE69535375D1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
RU95115239A (ru) Аналог эритропоэтина
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
HU9200548D0 (en) Improved activity process of recombined proteins
HK51197A (en) Platelet blocking peptides
DK525384D0 (da) Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
NZ235497A (en) Peptides (possibly related to hirudin) and pharmaceutical compositions for reducing blood coagulation
AU3629389A (en) Novel peptides suppressing the function of the immune system, pharmaceutical compositions containing them and process for preparing same
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
WO1990003394A3 (fr) Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines
NO952608L (no) Derivatiserte kalsitoniner

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 662827

Country of ref document: ES